DDInter542 DDInter107
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Dicoumarol {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Dicoumarol {u} (Compound) binds {v} (Gene) CRYZ
CRYZ {u} (Gene) is downregulated by {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may lead to a major life threatening interaction when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Apalutamide
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Dicoumarol (Compound) binds NQO1 (Gene) and NQO1 (Gene) is bound by Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Dicoumarol (Compound) binds CRYZ (Gene) and CRYZ (Gene) is downregulated by Isotretinoin (Compound) and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide